Alyeska Investment Group’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $53.3M | Sell |
235,000
-323,633
| -58% | -$57.6M | 0.14% | 191 |
|
|
2026
Q1 | $96.4M | Sell |
558,633
-86,093
| -13% | -$16M | 0.27% | 103 |
|
|
2025
Q4 | $129M | Buy |
644,726
+352,549
| +121% | +$64M | 0.36% | 68 |
|
|
2025
Q3 | $45.7M | Sell |
292,177
-535
| -0.2% | -$85K | 0.14% | 183 |
|
|
2025
Q2 | $44.4M | Buy |
+292,712
| New | +$39M | 0.16% | 171 |
|
|
2025
Q1 | – | Sell |
-200,262
| Closed | -$37M | – | 538 |
|
|
2024
Q4 | $37M | Buy |
+200,262
| New | +$38.6M | 0.14% | 181 |
|
|
2022
Q4 | – | Sell |
-333,429
| Closed | -$65.6M | – | 435 |
|
|
2022
Q3 | $65.6M | Buy |
333,429
+90,737
| +37% | +$19.6M | 0.77% | 30 |
|
|
2022
Q2 | $51.9M | Buy |
242,692
+126
| +0.1% | +$30.8K | 0.59% | 40 |
|
|
2022
Q1 | $68.9M | Buy |
242,566
+52,319
| +28% | +$16.1M | 0.76% | 26 |
|
|
2021
Q4 | $71.7M | Buy |
190,247
+79,335
| +72% | +$30.8M | 0.83% | 23 |
|
|
2021
Q3 | $45.8M | Buy |
110,912
+49,937
| +82% | +$20.7M | 0.57% | 43 |
|
|
2021
Q2 | $22.6M | Buy |
+60,975
| New | +$20.4M | 0.26% | 115 |
|
|
2020
Q3 | – | Sell |
-80,305
| Closed | -$14M | – | 485 |
|
|
2020
Q2 | $14M | Buy |
+80,305
| New | +$12.8M | 0.21% | 154 |
|
|
2020
Q1 | – | Sell |
-396,692
| Closed | -$60.6M | – | 387 |
|
|
2019
Q4 | $60.6M | Buy |
396,692
+157,716
| +66% | +$21.8M | 0.8% | 33 |
|
|
2019
Q3 | $31.6M | Buy |
238,976
+93,093
| +64% | +$12.5M | 0.46% | 80 |
|
|
2019
Q2 | $20.7M | Buy |
+145,883
| New | +$19.8M | 0.27% | 118 |
|
|
2018
Q4 | – | Sell |
-171,388
| Closed | -$23.1M | – | 384 |
|
|
2018
Q3 | $23.1M | Sell |
171,388
-328,488
| -66% | -$40.5M | 0.25% | 115 |
|
|
2018
Q2 | $56.1M | Sell |
499,876
-117,928
| -19% | -$12.7M | 0.5% | 71 |
|
|
2018
Q1 | $65.9M | Buy |
+617,804
| New | +$66.6M | 0.55% | 61 |
|
|
2017
Q3 | – | Sell |
-575,439
| Closed | -$58.2M | – | 473 |
|
|
2017
Q2 | $58.2M | Sell |
575,439
-171,037
| -23% | -$15.7M | 0.49% | 75 |
|
|
2017
Q1 | $67.1M | Sell |
746,476
-99,848
| -12% | -$8.48M | 0.55% | 53 |
|
|
2016
Q4 | $64.5M | Buy |
846,324
+254,519
| +43% | +$19.3M | 0.53% | 52 |
|
|
2016
Q3 | $49.3M | Sell |
591,805
-2,624
| -0.4% | -$220K | 0.46% | 63 |
|
|
2016
Q2 | $49M | Buy |
594,429
+18,194
| +3% | +$1.5M | 0.46% | 76 |
|
|
2016
Q1 | $43.8M | Buy |
576,235
+543,253
| +1,647% | +$40.2M | 0.4% | 83 |
|
|
2015
Q4 | $2.65M | Buy |
+32,982
| New | +$2.38M | 0.03% | 288 |
|
|
2014
Q2 | – | Sell |
-317,053
| Closed | -$19.1M | – | 408 |
|
|
2014
Q1 | $19.1M | Sell |
317,053
-32,947
| -9% | -$1.92M | 0.52% | 62 |
|
|
2013
Q4 | $18.6M | Buy |
350,000
+50,000
| +17% | +$2.51M | 0.73% | 31 |
|
|
2013
Q3 | $13.9M | Buy |
+300,000
| New | +$13.8M | 0.57% | 58 |
|
Other funds holding CRL
AI
Alyeska Investment Group's CRL Position: Q2 2026 in Review
Alyeska Investment Group reduced its Charles River Laboratories (CRL) stake by 58% in Q2 2026, selling an estimated $57.6M and leaving 235,000 shares worth $53.3M. The position accounts for 0.14% of the portfolio, ranked #191.
Alyeska Investment Group first reported a position in CRL in Q3 2013 and has held it in 29 quarters since. The position peaked at $129M in Q4 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Alyeska Investment Group held 235,000 shares of Charles River Laboratories worth $53.3M as of Q2 2026.
- Alyeska Investment Group sold 323,633 Charles River Laboratories shares in Q2 2026, an estimated $57.6M.
- Charles River Laboratories made up 0.14% of Alyeska Investment Group's portfolio in Q2 2026, its #191 holding.
- Alyeska Investment Group first reported a position in Charles River Laboratories in Q3 2013 and has held it in 29 quarters since.
- Alyeska Investment Group's Charles River Laboratories position peaked at $129M in Q4 2025.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.